Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Urology

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(01)64091-6PMID 9334576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma.

  1995cited by this paper
• Cytoreductive surgery for stage IV renal cell carcinoma.

  1995cited by this paper
• Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.

  1995cited by this paper
• The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma.

  1994cited by this paper
• Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.

  1993cited by this paper
• Interleukin‐2: Use in solid tumors

  1993cited by this paper
• Immunotherapy for metastatic renal cell cancer: effect on the primary tumor.

  1993cited by this paper
• Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.

  1993cited by this paper
• Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.

  1993cited by this paper
• A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.

  1993cited by this paper
• Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma

  1993cited by this paper
• Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

  1992cited by this paper
• Biologic Therapy of Cancer

  1992cited by this paper
• Immunotherapy and gene therapy of cancer.

  1991cited by this paper
• Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.

  1991cited by this paper
• Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma.

  1991cited by this paper
• Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

  1990cited by this paper
• Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.

  1990cited by this paper
• Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

  1990cited by this paper
• Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.

  1990cited by this paper
• Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.

  1990cited by this paper
• Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy.

  1990cited by this paper
• Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.

  1990cited by this paper
• Gene transfer into humans: a first step.

  1990cited by this paper
• Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients

  1989cited by this paper
• Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

  1989cited by this paper
• Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

  1988cited by this paper
• Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

  1988cited by this paper
• Interferon therapy of metastatic renal cell cancer.

  1988cited by this paper
• Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

  1988cited by this paper
• Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2

  1987cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Regression of metastatic renal cell carcinoma: a case report and literature review.

  1986cited by this paper
• Spontaneous regression of metastatic renal cell carcinoma.

  1982cited by this paper
• Treatment of advanced renal cell carcinoma.

  1982cited by this paper
• Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature

  1981cited by this paper
• Surgical resection for metastatic neoplasms of the lung: Experience at the university of minnesota hospitals

  1980cited by this paper
• The natural history of metastatic renal cell carcinoma: a computer analysis.

  1978cited by this paper
• The contribution of surgery to the management of carcinomatous pulmonary metastases

  1978cited by this paper
• Is nephrectomy justified in patients with metastatic renal carcinoma?

  1975cited by this paper
• NEPHROGENIC RIDGE TUMORS AND THEIR SYNDROMES

  1974cited by this paper
• Diagnosis and management of renal cell carcinoma A clinical and pathologic study of 309 cases

  1971cited by this paper
• Surgery for metastatic renal cell carcinoma.

  1967cited by this paper

• Cytoreductive nephrectomy in metastatic renal cell carcinoma.

  2024cites this paper
• Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC

  2023cites this paper
• Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.

  2022cites this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma

  2020cites this paper
• Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone.

  2020cites this paper
• Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma

  2020cites this paper
• Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.

  2019cites this paper
• Management of Non-Clear Cell Renal Cell Carcinoma

  2019cites this paper
• The use of cytoreductive nephrectomy in patients with renal cell carcinoma

  2019cites this paper
• Cytoreductive Nephrectomy and Metastasectomy for Renal Cell Carcinoma

  2018cites this paper
• Der symptomatische Nierentumor beim metastasierten Nierenzellkarzinom – chirurgische Optionen

  2018cites this paper
• Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach

  2017cites this paper
• Treatment of renal cell carcinoma: Current status and future directions

  2017cites this paper
• 2 Role of Laparoscopic Nephrectomy in Metastatic Renal Cell Carcinoma

  2017cites this paper
• Surgical management of metastatic renal cell carcinoma.

  2017cites this paper
• Kidney Metastatic Bone Disease

  2016cites this paper
• Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.

  2016cites this paper
• Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Review of the Historical Literature and Its Role in the Era of Targeted Molecular Therapy

  2014cites this paper
• Surgical management of metastatic renal cell carcinoma in the era of targeted therapies

  2014cites this paper
• Chemotherapy, Targeted Therapies, and Biological Therapies for Renal Cell Carcinoma

  2013cites this paper
• Consolidative surgery after targeted therapy for renal cell carcinoma.

  2013cites this paper
• Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α

  2013cites this paper
• Treatment of Advanced Renal Cell Carcinoma

  2012cites this paper
• New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer.

  2012cites this paper
• Malignant Renal Tumors

  2012cites this paper
• Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8+ T-cell immunity

  2012cites this paper
• Contemporary Management in Metastatic Renal Cell Carcinoma

  2012cites this paper
• Aus der Abteilung Nephrologie und Rheumatologie

  2011cites this paper
• Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre

  2011cites this paper
• Controlled Drug Delivery in Cancer Immunotherapy: Stability, Optimization, and Monte Carlo Analysis

  2011cites this paper
• Renal Neoplasia

  2011cites this paper
• Mortality and Morbidity After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study

  2011cites this paper
• [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].

  2010cites this paper
• Role of surgery in advanced/metastatic renal cell carcinoma

  2010cites this paper
• Multi-modal treatment for metastatic renal cancer: the role of surgery

  2010cites this paper
• Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

  2010cites this paper
• Molecular diagnosis and therapy of kidney cancer.

  2010cites this paper
• Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy

  2009cites this paper
• Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease

  2009cites this paper
• Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib

  2009cites this paper
• Role of cytoreductive nephrectomy in renal cell carcinoma.

  2009cites this paper
• Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.

  2009cites this paper
• The contemporary role of surgery in kidney cancer

  2009cites this paper
• Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma.

  2009cites this paper
• Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents

  2009cites this paper
• The role of cytoreductive nephrectomy in the era of molecular targeted therapy

  2009cites this paper
• Pre‐surgical targeted molecular therapy in renal cell carcinoma

  2009cites this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy

  2009cites this paper
• Integration of surgery and systemic therapy in the management of metastatic renal cancer

  2009influential citation
• Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy

  2009cites this paper
• Interferon-&agr; in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

  2008cites this paper
• Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.

  2008cites this paper
• Brain metastasis from renal cell carcinoma

  2008cites this paper
• Probability of Ten-Year Survival in Metastatic Renal Cell Carcinoma

  2008cites this paper
• Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Biologic Effects

  2008cites this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma

  2008cites this paper
• The once and future role of cytoreductive nephrectomy.

  2008cites this paper
• Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

  2007cites this paper
• Renal Cell Carcinoma Presenting with Paraneoplastic Hypercalcemic Coma: A Case Report and Review of the Literature

  2007cites this paper
• Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed

  2007cites this paper
• Whole cell profiling and identification of galectin‐1 as a potential marker of renal cell carcinoma

  2007cites this paper
• Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer

  2007cites this paper
• Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.

  2007cites this paper
• Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.

  2007cites this paper
• Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.

  2007cites this paper
• Adult Urology Cytoreductive Nephrectomy for T4NxM1 Renal Cell Carcinoma: The M.D. Anderson Cancer Center Experience

  2007cites this paper
• Renal cancer.

  2007cites this paper
• Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma

  2007cites this paper
• Renal cell cancer

  2006cites this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma

  2006cites this paper
• Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma : a consecutive study

  2006cites this paper
• Surgical management of renal cell carcinoma.

  2006cites this paper
• Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation

  2005cites this paper
• Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.

  2005cites this paper
• Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

  2005cites this paper
• Surgery for metastatic renal cell cancer

  2005cites this paper
• Lessons learned in the surgical management of renal cell carcinoma.

  2005cites this paper
• Combination of surgery and immunotherapy in metastatic renal cell carcinoma

  2005cites this paper
• Léčba metastazujícího karcinomu ledviny

  2004cites this paper
• Role of Laparoscopic Nephrectomy in Metastatic Renal Cell Carcinoma

  2004cites this paper
• Facteurs pronostiques cliniques et anatomo-pathologiques des cancers du rein avec thrombus cave

  2004cites this paper
• The role of lymphadenectomy in the surgical management of renal cell carcinoma.

  2004cites this paper
• Debulking Nephrectomy in Metastatic Renal Cancer

  2004cites this paper
• [Clinical and histological prognostic factors of renal cancer with caval thrombus].

  2004cites this paper
• Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy

  2004cites this paper
• Immunotherapy for urological malignancies.

  2004cites this paper
• A medical oncologist’s approach to immunotherapy for advanced renal tumors: Is nephrectomy indicated?

  2004cites this paper
• Cytoreductive nephrectomy in metastatic renal cancer

  2003cites this paper
• Role of nephrectomy in metastatic kidney cancer.

  2003cites this paper
• The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma.

  2003cites this paper
• Nephrectomy for metastatic renal cell carcinoma: Indiana University experience.

  2003cites this paper
• Metastatic renal cell carcinoma

  2003cites this paper
• Outcome and survival with nonsurgical management of renal cell carcinoma

  2003cites this paper
• Rapamycin is an effective inhibitor of human renal cancer metastasis.

  2003cites this paper
• The Timing of Immunotherapy and Nephrectomy in Multimodality Treatment of Metastatic Renal Cell Carcinoma

  2003cites this paper
• Phase II Trial of Subcutaneous Interleukin-2, Subcutaneous Interferon-α, 5-Fluorouracil and Cis-retinoic Acid in the Treatment of Renal Cell Carcinoma: Final Results of Cancer Biotherapy Research Group 94-10

  2002cites this paper
• Multimodality treatment of metastatic renal cell carcinoma

  2002cites this paper
• [The value of tumor nephrectomy in metastatic renal cell carcinoma].

  2002cites this paper
• Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.

  2002cites this paper
• Prognostic factors for biologic therapy in kidney cancer

  2002cites this paper